Abstract: Background/Aim: Pegylated interferon (Peg-IFN) plus ribavirin is the standard therapy for hepatitis C. Peg-IFN has several antiviral mechanisms, but its role in hepatitis C treatment seems to be related to its immunomodulatory effect. Ribavirin, an antiviral agent, potentiates IFN activity when added to it. Both drugs are associated with adverse reactions of different magnitudes. Autoimmune phenomena have been reported with this treatment. In this paper, we describe cases of ALT/GGT flares during Peg-IFN plus ribavirin treatment, which related to the appearance of anti-Golgi antibody and disease progress. Methods: We investigated three patients with hepatitis C and severe ALT/GGT flares during Peg-IFN and ribavirin treatment coinciding with anti-Golgi complex antibody as the only marker of autoimmunity. We then reviewed the medical files and tested anti-Golgi antibody in stored sera from 25 patients treated with conventional IFN and in 14 patients treated with Peg-IFN. Results: The three patients were male, over 45 years of age; all were relapsers and non-responders. Anti-Golgi antibody was positive during treatment coinciding with ALT/GGT flares but with hepatitis C virus (HCV)-RNA negativity, disappearing after stopping treatment, with normalization of ALT/AST levels. One patient had progression of fibrosis from F2 to F3 despite negativity of HCV-RNA. In the last group, only two patients treated with Peg-IFN experienced ALT/GGT flares but without anti-Golgi antibody Conclusions: The presence of antiGolgi complex antibody could be a marker of a temporary autoimmune phenomenon and progressive disease.
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Infection with hepatitis C virus (HCV) is an important public health problem worldwide (1). About 55-86% of HCV patients develop chronic infection (2) (3) (4) .
Chronic HCV is usually characterized by a lack of symptoms or only fatigue or abdominal pain. Extra hepatic manifestations are well known and primarily associated with autoimmune or lymphoproliferative states such as arthritis, autoimmune thyroiditis, diabetes mellitus, idiopathic thrombocytopenic purpura, myasthenia gravis, Sjogren syndrome, aplastic anemia, essential mixed (type II) cryoglobulinemia, monoclonal gammopathy and non-Hodking lymphoma. Dermatological manifestations include erythema multiforme, erythema nodosun, Lichen Planus, Porphyria cutanea tarda, psoriasis, pruritus and vasculitis. Idiopathic pulmonary fibrosis and membranoproliferative glomerulonephritis have also been reported (5) .
Patients with chronic HCV infection do have a higher prevalence rate of autoantibodies in the serum (6) . The determination of the antinuclear antibody has thus been recommended before starting HCV therapy (7) .
Since 1999, interferon (IFN) plus ribavirin is considered as the standard of care for hepatitis C (8) . IFN has several antiviral mechanisms, but its role in hepatitis C treatment seems to be related to its immunomodulatory effect (9) . Despite its broad spectrum of antiviral activity, ribavirin has a negligible direct antiviral action against HCV replication when used in monotherapy. In contrast, it potentiates IFN activity when added to it, suggesting an additional immunomodulatory effect (10).
Both drugs are related to adverse reactions of different magnitudes. Among these sideeffects, anemia, neutropenia, thrombopenia, depression and fatigue are the most common, but less frequent adverse reactions related to autoimmune phenomena have been frequently reported.
Therapy with IFN-a does also induce autoantibodies in more than half of the patients treated for chronic hepatitis C. Common antibodies are antithyroid, antinuclear antibodies and antibodies against insulin. In the majority of these patients, no evidence of autoimmune disease will develop. However, in susceptible patients, autoimmune features may occur (11, 12) .
Another unusual side-effect is autoimmune hepatitis, which can prompt immediate discontinuation of the treatment (13) . Antithyroid antibodies and autoimmune thyroiditis seem to be the most common side-effects attributable to the immunomodulatory role of IFN. Autoimmune hemolytic anemia and immune-mediated thrombocytopenia purpura were related to this therapy. Autoimmune arthritis including rheumatoid arthritis can emerge during IFN-a therapy as well as systemic lupus erythematosus-like syndrome. Diabetes mellitus may worsen or develop during this therapy (11) (12) (13) (14) (15) (16) .
More recently, Pegylated interferon (Peg-IFN) replaced the conventional one because of best results in terms of sustained virological response (17, 18) . Although these newer agents are significantly more effective than earlier versions of standard IFN, the side-effect profile of IFNbased therapies has remained unchanged despite increased incidence of AES. Thus, influenza-like symptoms (fever, myalgia and rigor) and several gastrointestinal disturbances occur with increased frequency (Po0.05) in those treated with Peg-IFN combination therapy compared with standard IFN and ribavirine (19) (20) (21) .
New side-effects of this therapy are reported continuously with the acknowledgment of the results of the different trials (22) .
During Peg-IFN plus ribavirin treatment, some ALT and GGT elevations are observed, but its mechanism remains unknown (18) . Such liver enzyme elevations do not seem to alter antiviral response and even mild to moderate flares are considered benign as they are not related to liver disease progression.
In this paper, we described cases of ALT/GGT flares during Peg-IFN plus ribavirin treatment, which were related to anti-Golgi antibody appearance and progressive liver disease. Interestingly, the Golgi apparatus may serve as the starting site of morphological changes associated with viral infection and replication leading to cell fusion and syncytia formation.
Patients and methods

Patient 1
A 49-year-old male patient, BMI 25, was genotype HCV 1a (INNOLIPA, Innogenetic, Belgium), treated in 1999 with conventional IFN plus ribavirin for 48 weeks. Although he responded during therapy, he relapsed within 3 months of stopping treatment. Pretreatment liver biopsy was graded A2F4 by METAVIR score. The genotype of HCV was 1a (INNOLIPA, Innogenetic, Belgium).
In 2005, he was retreated with Peg-IFN-a2a, once a week, plus ribavirin 1.0 g/day. At week 12, he had cleared HCV-RNA (qualitative PCR, Amplicor, Roche, Basel, Switzerland). But he presented ALT flares 410 times the UNL. Concomitantly, GGT increased 15 times the UNL. Other causes of liver injury, such as viral hepatitis of other etiology and billiary obstruction, were ruled out. He had no symptoms, except fatigue.
He was investigated for evidence of autoimmunity with anti-TPO, ASMA and ANA, which were all found to be negative. Thyroid function tests were also normal. Autoimmunity profile was repeated and showed an immunofluorescence pattern compatible with anti-Golgi antibody in HEP cells (Fig. 1, golgi) .
This autoantibody persisted during the whole treatment duration, while liver enzymes kept fluctuating from five to 10 times the UNL. Treatment was indeed maintained up to week 48, as HCV-RNA (Amplicor, Roche) was persistently negative. After stopping treatment, ALT returned to normal but GGT remained elevated but less than three times the UNL. Around 3 months after stopping treatment, a new ALT flare was observed. At this time, HCV-RNA became positive, confirming a viral relapse, but no antiGolgi complex antibody was observed anymore (Fig. 2, graphic) .
This patient presented no other side-effect potentially related to the antiviral treatment, except mild anemia, which did not require dose reduction of ribavirin.
Patient 2
A 52-year-old male patient, genotype HCV 1a (INOLIPA, Innogenetic) BMI 28, never treated before, initiated antiviral therapy in 2004 with Peg-IFN-a2a, once a week, plus ribavirin 1.0 g/ day. Pretreatment, liver biopsy was scored A2F2 by METAVIR. Despite clearing HCV-RNA (qualitative PCR, Amplicor, Roche) at week 12, he presented ALT flare 420 times the UNL. Concomitantly, GGT increased 10 times the UNL. Other common causes of liver injury including basic auto-antibodies panel were ruled out as described for patient 1. He had moderate fatigue, cough and xerophthalmia.
He was then reinvestigated again for autoimmunity with anti-TPO, anti-SSA, anti-SSB, ASMA and ANA with negative results. Thyroid function tests were normal. AMA was repeated 2 weeks later because of a mild pruritus, and examination revealed the appearance of a new immunofluorescence pattern of anti-Golgi antibody in HEP cells.
This autoantibody persisted during the whole treatment, while the liver enzymes increased to up to 30 times the UNL, and HCV-RNA (Amplicor, Roche) remained undetectable. A liver biopsy was performed during treatment (week 35) and showed evidence of necro-inflammation with fibrosis progression to A2F3 according to META-VIR (Figs 3 and 4) . The liver fragment had eight portal spaces and the second one had 12 portal spaces. The slides were revised by two experienced liver pathologists in a referral center for liver pathology.
The HCV-RNA was repeated again and remained negative. g-globulin increased and antiGolgi complex antibody persisted. Treatment was stopped at week 36. The liver enzymes progressively deceased to three times the UNL for ALT and five times the UNL for GGT. The anti-Golgi complex antibody disappeared after stopping treatment. Around 2 months after stopping treatment, a new ALT flare (10 times the UNL) was observed. At this time, HCV-RNA became positive, confirming a viral relapse, but no anti-Golgi complex antibody was observed anymore (Fig. 5,  graphic) .
This patient had no other adverse event potentially related to antiviral therapy. Mild anemia was observed but no ribavirin dose reduction was indicated. Besides fatigue, xerophthalmia, and thrombopenia, he also had transient artrhalgia with no arthritis.
Patient 3
A 62-year-old male patient, BMI 25 genotype HCV 1a (INOLIPA, Innogenetic), never treated before, was initiated on anti-viral treatment in 2005 with Peg-IFN-a2a, once a week, plus ribavirin 1.0 g/day. Before treatment, liver biopsy showed A2F2 by METAVIR score.
Despite of a two-log decline in his viral load at week 12 (quantitative RT-PCR, Amplicor, Roche), he presented an ALT flare 420 times the UNL. Concomitantly, GGT increased 20 times the UNL. Other causes of liver injury were ruled out as described in patients 1 and 2. He had fatigue and thrombopenia.
He was then investigated for autoimmunity with anti-TPO, ASMA and ANA, which were all negative, except for anti-Golgi complex antibody, which was positive. Thyroid function tests were normal. The patient was still viremic at week 24 and also presented neutropenia besides thrombopenia and more intense fatigue. The treatment was interrupted. After stopping treatment, liver enzymes remained silently elevated, but anti-Golgi complex antibody disappeared. Viremia persisted (Fig. 6, graphic) .
Based on these results, we retrospectively reviewed the medical files and performed investigation for anti-Golgi antibody in stored sera from 25 patients treated with conventional IFN plus ribavirin, in 14 patients treated with Peg-IFN-a2a and 21 patients with a2b. No patient treated with conventional IFN presented mild or moderate ALT flare in these samples, but two patients treated with IFN-a2a and one with a2b presented ALT and/or GGT flares from weeks 4 to 24 during treatment. In these patients liver enzymes were always below 10 times the UNL. Anti-Golgi antibody as well as ANA and ASMA were also negative in all of them regardless of ALT/GGT flares (Fig. 7) .
Discussion
In this paper, we described cases of severe ALT/ GGT flares higher than 10 ULN during Peg-IFNa2a plus ribavirin treatment, which were related to anti-Golgi antibody appearance and progression of liver disease. Anti-Golgi antibodies were first described in a patient with Sjogren syndrome and lymphoma, and were subsequently demonstrated in other clinical conditions (23) .
Anti-Golgi complex antibody has been described in some autoimmune disease such as rheumatoid arthritis and systemic lupus erythematosus, but does not seem to be a specific marker so far (24, 25) . We had observed antiGolgi complex antibodies in a few cases of cryptogenic hepatitis (data not published).
They have also been detected in malignancies. Mozo et al. (26) described the presence of high titers of anti-Golgi antibodies in a patient with virus C-induced hepatocellular carcinoma (HCC). They found an overall frequency of anti-Golgi antibodies in their series of patients with virusinduced HCC of 5.5%. The appearance of antiGolgi in these patients could be induced by the virus itself or it could be a phenomenon associated with malignant transformation and or repeated IFN therapy failures. Close follow-ups of these patients are warranted in order to screen HCC.
It was demonstrated that the Golgi apparatus may serve as the starting site of morphological changes associated with viral infection and replication, leading to cell fusion, syncitia formation and finally lysis of infected cells and virus release (27) .
The ALT/GGT elevations during Peg-IFN plus ribavirin treatment have no explanation, but are generally considered a nonhazardous phenomenon, as mentioned before, especially as most of the time they are mild o10 ULN.
In contrast, the ALT flare during IFN treatment for hepatitis B is related to the host stimulation of the immune system, which makes these phenomena a predictive marker of sustained response (28) .
These ALT elevations are more commonly reported with Peg-IFN-a2a compared with a2b. This may raise questions regarding a possible hepatotoxicity of 40 kDa Peg-IFN, as it is almost completely metabolized by the liver (29) .
A more likely explanation in our cases is autoimmunization triggered by IFN therapy. Hashimoto thyroditis, autoimmune hepatitis, celiac disease and many other autoimmune diseases have been described during IFN (13, 14, 30, 31) . Among all described autoimmune diseases exacerbated or promoted by IFN therapy, autoimmune hepatitis is rarely described.
In these presented cases, we observed severe ALT flares together with even worse elevations of 1a to 20 ULN of GGT. All patients were male, over 45 years of age and all were relapsers or nonresponders to a previous course of treatment. Anti-Golgi complex antibody disappeared after stopping treatment and no other autoimmunity marker could be found. The disappearance of the anti-Golgi complex antibody after stopping treatment and its absence in all other studied cases do suggest that it is related to the severe flares of ALT/GGT during treatment. An important contribution of this paper is that as documented histologically in one patient, this phenomenon was clearly associated with necro-inflammation and progressive fibrosis. This patient had a liver biopsy during the flare, and at the time of antiGolgi positivity, HCV-RNA was found to be negative. A second biopsy showed necro-inflammation and progression of fibrosis from F2 to F3 by METAVIR score in a blind analysis performed by two experimented pathologists. The explanation for this phenomenon remains a matter of speculation. Certainly, a transient autoimmune reaction must be considered. The presence of anti-Golgi complex antibody only during treatment and the coincident decrease of ALT after anti-Golgi complex antibody disappearance strongly argue in favor of this hypothesis. On the other hand, the Golgi complex is now recognized as an intracellular site for viral replication (15) . Then, we could speculate that strong host system stimulation could have the Golgi complex as a target. In these cases, anti-Golgi complex antibody could be the result of its insult induced by specific antiviral response, while the autoantibodies generated could be an epiphenomenon due to mere bystander collateral damage. Against this hypothesis is the fact that none of the patients achieved sustained response. Although only three cases were studied, there is no evidence in favor of immunoclearance phenomena as described in hepatitis B flares during IFN treatment. The patient who had a liver biopsy during treatment showed histopathological features of progressive chronic liver disease and not a pattern of immunoclearance as lobular activity was not important (32) .
Moreover, autoimmunity and extra-hepatic manifestations in hepatitis C infection are related to some impairment of the host's TH1 immune response generation (33) . Such events are probably associated with less sustained virological response as observed in these three cases.
In conclusion, severe ALT/GGT flares during regulated IFN therapy for hepatitis C cannot always be considered a benign phenomenon. The presence of anti-Golgi complex antibody in these cases is intriguing, but suggests that it could be a marker of temporary autoimmune phenomena, associated with liver fibrosis progression.
This observation warrants further studies in order to define the incidence of this autoantibody during IFN plus ribavirin therapy, as well as its role as a pathogenic marker of a new Peg-IFN-a triggered autoimmune manifestation in hepatitis C.
